High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma

J. R. Mills, D. R. Barnidge, A. Dispenzieri, D. L. Murray

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


We assessed the ability of a mass spectrometry-based technique, called monoclonal immunoglobulin rapid accurate mass measurement (miRAMM), to extend the analytical range of M-protein detection in serum samples obtained from myeloma patients in stringent complete response (sCR) post-autologous stem cell transplant (ASCT). To aid the M-protein detection post ASCT, the accurate molecular mass of the M-protein light chain at diagnosis was determined in all patients (N=30) and used to positively identify clones in the sCR serum. Day 100 post-ASCT, sCR samples had miRAMM identifiable M-proteins in 81% of patients. Patients who had achieved only a partial remission (PR) pre-ASCT and those with IgG isotypes serum samples had the highest rate of M-protein detection by miRAMM. miRAMM positivity at single time points (day 100, 6 months or 12 months) did not correlate with progression-free survival (PFS). In contrast, sCR patients who did not decrease their miRAMM M-protein intensities in serial measurements had shorter PFS than those whose miRAMM intensities decreased (median 17.9 months vs 51.6 months; P<0.0017). miRAMM M-protein is a more sensitive blood-based test than traditional M-protein tests and could cost effectively aid in serially monitoring complete remission for continue response or biochemical relapse.

Original languageEnglish (US)
Article numbere590
JournalBlood cancer journal
Issue number8
StatePublished - Aug 25 2017

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma'. Together they form a unique fingerprint.

Cite this